Economic development creates opportunities to grow state, local and metro areas, which are essential for economic growth, improved quality of life and community development. pharmaceuticals articles below.
Industry analysts are predicting that 2018 will turn out to be a banner year for merger and acquisition activity in the biotech/pharma sector, with up to $200 billion in assets changing hands.
The pharmaceutical company will expand its capabilities in biologics through a new biotech center at its global headquarters and manufacturing site in St Prex, Switzerland.
OurPharma will invest $31.3 million in a new facility, and create 124 new jobs in Fayetteville over the next seven years.
The regenerative medicine company's expansion of its Virginia Beach global headquarters is the 1,000th economic development project of the McAuliffe administration.
The Fortune 500 company is investing more than $45M and will create over 120 jobs at its new Whitestown, IN facility.
The Arkansas-based company will lease a 90,000-square-foot facility in Windsor, CT, where it will create approximately 361 new jobs over the next four years.
The pharmaceutical company will invest $35 million to expand its Fairfax County, VA R&D and manufacturing operation.
The pharmaceutical giant’s significant investment in manufacturing diabetes medicines will continue with a new $85 million commitment in Indianapolis.
Vetter plans to invest $320 million and create 300 jobs at its Des Plaines, IL manufacturing facility.
McKesson Corporation will open a new 340,000-square-foot distribution center and create 160 new jobs in Orange County, NY.
The Sunshine State’s Atlantic Coast is successfully competing with an international market for new business in a surging biotech sector.
Jones Lang LaSalle's 2012 Life Sciences Cluster Report shows greater Boston, San Diego, Philadelphia and Raleigh-Durham rising in importance as industry hubs.
High tech customer center will serve as catalyst to spur pharmacy and health care innovation.
The global financial contraction put a squeeze on seed money for biotech startups, forcing locations to build their biotech future the old-fashioned way: with long-term planning and a comprehensive strategy for growth. From the May/June 2012 issue.